BioAge Labs, Inc.(BIOA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,607 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
BIOA Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for BioAge Labs, Inc. (BIOA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BIOA at 26.8/100 on a 32-signal composite quality model, placing it at rank #2,607 of 2,962 stocks — the bottom half of the AI-ranked universe. BIOA scores in the top quartile across revenue growth (95.1), institutional flow (85.8). Areas of concern include free cash flow (2.0) and revenue scale (2.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BioAge Labs, Inc. reports quarterly revenue of $2.5M, net income of $-26.1M, free cash flow of $-19.6M. Top institutional holders of BIOA by reported 13-F value include a16z Capital Management, L.L.C., BlackRock, Cormorant Asset Management, based on the most recent SEC filings. BIOA trades on the Nasdaq exchange and files with the SEC under CIK 1709941. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BIOA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BioAge Labs, Inc. directly from SEC EDGAR. BioAge Labs, Inc.'s 13F Pro composite quality score has ranged between 14 and 29 since 2026, currently 26.8 — a stable long-term trajectory across 25 quarterly and live scoring snapshots.
Revenue
Q2 2026
$2.5M
Net Income
Q2 2026
$-26.1M
Free Cash Flow
Q2 2026
$-19.6M
ROIC
Q2 2026
-31.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-13.4% YoYOperating Income
-18.7% YoYEPS (Diluted)
+66.2% YoYTotal Assets
-17.7% YoYTotal Debt
-81.7% YoYOp. Cash Flow
-58.4% YoYFree Cash Flow
-58.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $9.0M | $0.00 | — | — |
| Net Income | $-80.6M -13.4% | $-71.1M -11.4% | $-63.9M | — |
| Operating Income | $-92.8M -18.7% | $-78.2M -61.6% | $-48.4M | — |
| EPS (Diluted) | $-2.24 +66.2% | $-6.63 +82.6% | $-38.17 | — |
| Total Assets | $294.9M -17.7% | $358.2M +1281.9% | $25.9M | — |
| Total Debt | $2.6M -81.7% | $14.5M +2.1% | $14.2M | — |
| Operating Cash Flow | $-81.6M -58.4% | $-51.5M -37.9% | $-37.4M | — |
| Free Cash Flow | $-82.3M -58.7% | $-51.9M -38.3% | $-37.5M | — |
Get alerted when BIOA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for BioAge Labs, Inc. including:
Top Institutional Holders of BIOA
a16z Capital Management, L.L.C.
$79.2M3,233,170 shBlackRock, Inc.
$69.8M2,849,077 shCormorant Asset Management, LP
$58.6M2,390,605 shSofinnova Ventures Inc
$56.2M2,293,788 shJupiter Topco LLC
$52.6M2,144,633 shOctagon Capital Advisors LP
$42.8M1,748,000 shRA CAPITAL MANAGEMENT, L.P.
$41.0M1,671,648 shMPM BioImpact LLC
$40.9M1,667,661 shVANGUARD CAPITAL MANAGEMENT LLC
$37.8M1,544,214 shPolar Capital Holdings Plc
$26.3M1,072,344 sh
| Fund | Value | Shares |
|---|---|---|
| a16z Capital Management, L.L.C. | $79.2M | 3,233,170 |
| BlackRock, Inc. | $69.8M | 2,849,077 |
| Cormorant Asset Management, LP | $58.6M | 2,390,605 |
| Sofinnova Ventures Inc | $56.2M | 2,293,788 |
| Jupiter Topco LLC | $52.6M | 2,144,633 |
| Octagon Capital Advisors LP | $42.8M | 1,748,000 |
| RA CAPITAL MANAGEMENT, L.P. | $41.0M | 1,671,648 |
| MPM BioImpact LLC | $40.9M | 1,667,661 |
| VANGUARD CAPITAL MANAGEMENT LLC | $37.8M | 1,544,214 |
| Polar Capital Holdings Plc | $26.3M | 1,072,344 |
Companies Similar to BIOA
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Zenas BioPharma, Inc.
Evommune, Inc.
Pelthos Therapeutics Inc.
Taysha Gene Therapies, Inc.
ALUMIS INC.
Relay Therapeutics, Inc.
Prelude Therapeutics Inc
ImageneBio, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put BIOA on your watchlist
Track score changes the day BioAge Labs, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BIOA a good stock to buy?
13F Pro's AI-powered analysis of BioAge Labs, Inc. (BIOA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BIOA are available on the BIOA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BIOA is classified as a small company.
Which hedge funds own BIOA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BIOA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BioAge Labs, Inc.'s investment landscape.